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Abstract Psoriasis is associated with an increase of Th17
cytokines, such as IL-17, IL-22, IL-21, and TNF-a, which
are produced by Th17 cells. Adipokines are peptide hor-
mones or cytokines secreted from adipose tissues and
involved in the pathogenesis of metabolic syndrome (MS).
Psoriasis patients have a high prevalence of the MS. In
this study, we investigated the statistics of circulating
Th17-related cytokines and adipokines in psoriasis
patients. Our study identiﬁed the signiﬁcant elevation of
serum IL-6, IL-21, IL-22, and resistin levels in psoriasis
patients. Increased serum levels of IL-22 and adiponectin
were positively correlated with Psoriasis Area and Severity
Index (PASI). In contrast, serum high molecular weight
adiponectin levels were decreased in psoriasis and nega-
tively correlated with PASI.
Keywords IL-6  IL-21  IL-22  Resistin  Adiponectin 
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Introduction
There has been a growing number of evidence that IL-17-
producing type 17, helper T (Th17) cells play an important
role in the pathogenesis of psoriasis [8]. Th17 cells dif-
ferentiate from naı ¨ve CD4? T cells under the stimulation
of IL-1b, IL-6, and IL-23, and their proliferation and
maturation are further driven by IL-23. They can produce
IL-17, IL-22, IL-21, and TNF-a. IL-22 ﬁnally induces
hyperplasia, abnormal differentiation and the expression of
many antimicrobial peptides, such as S100 family proteins
and b-defensin family proteins from keratinocytes [1].
Metabolic syndrome (MS) has been reported to be
associated with an increased risk of psoriasis [4, 7, 15]. A
recent study by Love et al. [7] demonstrated that the
prevalence of MS was 40% among psoriasis patients,
whereas 23% among the controls. Adipokines are cyto-
kines derived from adipose tissues and involved in the
pathogenesis of MS, however, the impact of adipokines on
the psoriatic etiology remains unsolved. We previously
demonstrated that serum levels of some adipokines, such as
chemerin and leptin, were upregulated in psoriasis patients
[9]. In this study, we investigated alternation of circulating
cytokines (TNF-a, IL-6, IL-17, IL-21, IL-22, and IL-23)
and adipokines (retinol-binding protein-4: RBP-4, resistin,
chemerin, and leptin; adiponectin and high molecular
weight adiponectin: HMW adiponectin) in psoriasis
patients, and their correlation with MS.
Patients and methods
All the procedures received approval from the Ethics
Committee of Kochi Medical School, and all the subjects
provided written informed consents. Fasting serum samples
were obtained from psoriasis patients (n = 30), sex- and
weight-matched control subjects (n = 30), and analyzed
by enzyme-linked immunosorbent assay method (TNF-a,
IL-6, IL-17, IL-22, IL-23 and RBP4: R&D Systems, Inc.,
MN. USA; IL-21: Bender Med Systems GmbH, Vienna,
Austria, resistin: BioVendor, NC, USA; chemerin: Milli-
pore Corporation, Billerica, MA, USA; leptin: B-Bridge
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and HMW adiponectin: Otsuka Pharmaceutical Co., Ltd.,
Tokyo, Japan). The serum chemistry and complete blood
count tests were performed. Weight, height, body mass
index (BMI), and waist circumferences of all the individ-
uals were recorded. Disease severity was assessed with the
Psoriasis Area and Severity Index (PASI) by the same
physician.
Results
Patients with psoriasis presented higher levels of serum
TNF-a, IL-6, IL-21, IL-22, resistin, RBP-4, chemerin, and
leptin (Table 1). Circulating IL-17 and IL-23 levels were
below the detectable limits in both the groups in our
experimental settings. Serum IL-6, IL-21, IL-22, resistin,
chemerin and leptin levels were signiﬁcantly elevated in
patients with psoriasis when compared with the controls.
On the other hand, serum TNF-a and RBP-4 levels were
not signiﬁcantly different. In contrast to the previous
studies, total adiponectin levels in patients with psoriasis
were not signiﬁcantly different from the controls. However,
HMW adiponectin levels were signiﬁcantly lower in pso-
riasis patients when compared with those in controls
(Table 1). Serum IL-21 level in the patients was not pos-
itively correlated with PASI score (Fig. 1a). However, we
observed a positive correlation between IL-22 and PASI
score (Fig. 1b). Serum levels of TNF-a (Fig. 1c), resistin
(Fig. 2a, b) and RBP-4 levels (Fig. 2c, d) were not posi-
tively correlated with PASI score or BMI in psoriasis
patients. Furthermore, serum resistin and RBP-4 levels
were not different between the patients with and without
hyperglycemia (data not shown). Serum total adiponectin
levels were positively correlated with PASI score (Fig. 2e),
and showed slightly negative correlation with BMI in
patients with psoriasis (Fig. 2f). On the other hand, HMW
adiponectin levels were negatively correlated with PASI
score and BMI in psoriasis patients (r =- 0.296 and
r =- 0.267). HMW adiponectin levels were also nega-
tively correlated with BMI in the controls (r =- 0.230). A
positive correlation between waist circumferences and
serum levels of resisitin, RBP-4 and leptin was found in
psoriasis patients and controls. Serum levels of total
adiponectin and HMW adiponectin were negatively cor-
related with the waist circumferences in psoriasis patients
and controls.
Discussion
Our study indicated that patients with psoriasis showed
higher IL-22 levels than the controls, and that IL-22 values
positively correlated with PASI score, in accordance with
the previous report [19]. This result suggested that serum
IL-22 was a good marker of the clinical severity of psori-
asis. No detectable serum levels of IL-17 or IL-23 were
found in both the groups. There are possibilities that such
cytokines might be involved in the very early phase of
psoriasis development or be present only in the lesional
skin [10]. TNF-a levels were negatively correlated to the
PASI, inconsistent with the results of Takahashi et al. [18].
Table 1 Serum levels of Th17-related cytokines and adipokines
Controls (n = 30) Psoriasis patients (n = 30) p value
TNF-a (pg/ml) 3.95 ± 0.48 17.80 ± 12.50 0.364
IL-6 (pg/ml) 2.85 ± 0.50 13.38 ± 4.67 \0.0001**
IL-17 (pg/ml) UD UD
IL-21 (pg/ml) UD 32.7 ± 18.01 0.031*
IL-22 (pg/ml) 2.50 ± 0.66 24.14 ± 12.74 0.006**
IL-23 (pg/ml) UD UD
Resistin (ng/ml) 3.44 ± 0.37 5.44 ± 0.58 0.022*
RBP-4 (ng/ml) 23.31 ± 1.95 31.69 ± 3.82 0.079
Chemerin (ng/ml) 120.79 ± 6.40 188.05 ± 7.78 \0.0001**
Leptin (ng/ml) 9.58 ± 1.72 22.84 ± 3.55 0.005**
Adiponectin (lg/ml) 8.49 ± 1.19 9.46 ± 1.03 0.261
HMW-adiponectin (lg/ml) 6.31 ± 0.66 3.58 ± 0.37 0.001**
Serum IL-6, IL-21, IL-22, resistin, chemerin and leptin levels were signiﬁcantly higher in psoriasis patients (n = 30) when compared with the
controls (n = 30). Serum HMW adiponectin levels were signiﬁcantly lower in psoriasis patients when compared with the controls. Values
represent the mean ± SEM. Statistical analysis was generated with Mann–Whitney test: * p B 0.05 and ** p B 0.01
UD under the detection limit
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123The main reason for this discrepancy is due to relatively
low levels of serum TNF-a in most of the psoriasis patients
except for one patient with extremely high TNF-a values
(379 pg/ml). On the other hand, a positive correlation was
found between serum TNF-a levels and PASI (r = 0.179),
when we limited to mild psoriasis patients (PASI score
B10). We found a signiﬁcant elevation of serum IL-21 and
resistin levels in patients with psoriasis as compared to the
controls.
Resistin was originally discovered in mouse adipocytes
and assigned a role in the induction of murine insulin
resistance [16]. Furthermore, it was reported that resistin
stimulated the activation of macrophages to promote the
secretion of proinﬂammatory cytokines [14]. Our ﬁnding in
resistin conﬁrms the pattern observed in a previous study
[5]. There was no signiﬁcant difference in RBP-4 levels
between patients and controls, consistent with the result by
Rollman et al. [12]. Microarray studies found high levels of
RBP-4 expression in the adipose tissue of insulin-resistant
glucose transporter 4 (Glut4) knockout mouse [20]. Recent
studies have shown that serum RBP-4 levels were elevated
in diabetes and obesity, whereas relationship between
RBP-4 and insulin resistance still remains controversial
[21]. Our results showed that there was no signiﬁcant
correlation between hyperglycemia and levels of RBP-4 in
psoriasis patients.
Total adiponectin levels did not differ signiﬁcantly
between psoriasis patients and controls in this study.
Adiponectin possesses insulin-sensitizing and anti-inﬂam-
matory effects. Several studies have demonstrated that
adiponectin was decreased in psoriasis [13, 17]. A study
reported that serum adiponectin levels in normal-weight
psoriasis patients were rather increased as compared to the
healthy controls [6], which was consistent with our result.
On the contrary, HMW adiponectin levels were signiﬁ-
cantly lower in our psoriasis patients as reported by Shibata
et al. [13]. Our study indicated slightly negative correlation
between total adiponectin and BMI in psoriasis. In addi-
tion, serum levels of HMW adiponectin were negatively
correlated with BMI in psoriasis patients. Circulating
adiponectin is decreased in obesity and diabetes, and it
negatively correlates BMI [11]. Adiponectin levels were
positively associated with PASI in our study, in contrast to
the previous reports [2, 15]. However, we found a negative
correlation between serum high MW adiponectin levels
and PASI. HMW adiponectin is suggested to be a more
useful and sensitive marker for obesity and clinical severity
in psoriasis. Although there was no negative correlation
Fig. 1 Correlation between serum levels of cytokines and PASI
score in psoriasis patients. Serum IL-21 levels did not positively
correlate with PASI score in psoriasis patients (a). Serum IL-22 levels
positively correlate with PASI score in psoriasis patients (b). Serum
TNF-a levels did not positively correlate with PASI score in psoriasis
patients (c)
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(r = 0.017), a slightly negative correlation was found
(r =- 0.069) between serum HMW adiponectin levels and
IL-6 levels. Interestingly, a strong positive correlation was
found between serum total adiponectin levels and IL-6
levels (r = 0.6397), when we limited to moderate to severe
psoriasis patients (PASI score C10). These results showed
that the properties of HMW adiponectin and total
Fig. 2 Correlation between serum adipokine levels, PASI score, and
BMI in psoriasis patients. Serum resistin levels did not positively
correlate with PASI score (a). Correlation between serum levels of
resistin and BMI in psoriasis patients (open circle), and normal
controls (open triangle)( b). Serum resistin levels positively correlate
with BMI in normal controls, although there was no positive
correlation with BMI in psoriasis patients. Serum RBP-4 levels did
not positively correlate with PASI score (c). There was no positive
correlation between RBP-4 levels and BMI in psoriasis patients (d).
Serum adiponectin levels positively correlated with PASI score in
psoriasis patients (e). Serum adiponectin levels negatively correlate
with BMI in normal controls, although there was slightly negative
correlation in psoriasis patients (f)
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be speculated that low and medium MW adiponectin pro-
ductions are upregulated and that they do not have anti-
inﬂammatory effects in our psoriasis patients. Gerdes et al.
[3] reported that increased levels of adiponectin were found
in autoimmune and chronic inﬂammatory diseases, such as
rheumatoid arthritis, systemic lupus erythematosus and
inﬂammatory bowel disease, which were unrelated to
increased adiposity. Total adiponectins other than HMW
adiponectin may be upregulated in chronic inﬂammatory
conditions.
In summary, serum IL-21, IL-22 and resistin levels were
signiﬁcantly elevated in psoriasis patients. Our ﬁndings
suggested that serum IL-22 levels were correlated with
clinical severity in patients with psoriasis. Serum adipo-
nectin levels were positively related to PASI score. In
contrast, serum HMW adiponectin levels were decreased in
psoriasis patients and negatively correlated with PASI. It is
possible that the biological effect of adiponectin could be
dissected based on its molecular weight.
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